ABSTRACT
Crisis helplines provide important support for vulnerable individuals during the COVID-19 pandemic, which may also impact the helplines. We explored the challenges that the pandemic brought to Taiwan's national suicide prevention hotline and the hotline's responses. We interviewed 14 hotline workers and conducted data analysis using the framework method. The pandemic posed two new challenges to the hotline: potential service interruption and the adjustment of perceived role among hotline workers. The hotline's well-formulated response plan helped it sustain its services during the pandemic, although the workers also experienced stress and frustration resulted from role ambiguity. Our data highlighted the hotline workers' need for accurate COVID-19 information, relevant training, and timely support.
ABSTRACT
Background: The COVID-19 pandemic and its consequences may affect population mental health and suicide risk. Aims: To explore the experiences among suicidal individuals who made calls to a suicide prevention hotline and to identify factors and psychological responses that may influence suicide risk. Method: We identified 60 eligible recorded calls to Taiwan's suicide prevention hotline (January 23, 2020-May 31, 2020) and analyzed the transcripts using a framework analysis. Results: We identified three themes: (a) effects of the COVID-19 pandemic on society (impacts on local economies, the fear of contagion, and disruptions caused by outbreak control measures); (b) stress experienced by callers, including increased challenges (financial burden, restricted freedom of movement, interpersonal conflicts, feelings of uncertainty, and education/career interruption) and reduced support (reduced access to health services and social support); and (c) the callers' psychological responses to stress, including anxiety, sleep disturbance, depression, loneliness, hopelessness, and entrapment, which may increase suicide risk. Limitations: Only the experiences among those who sought help by calling the hotline during the early months of the pandemic in 2020 were explored. Conclusion: Our findings revealed the potential process underlying the impact of the COVID-19 pandemic on suicide risk and have implications for prevention and intervention strategies.
ABSTRACT
IntroductionHyaluronic acid (HA) is one of the main components of glycosaminoglycan (GAG) in proteoglycans. Among patients with novel coronavirus pneumonia, the serum HA content of severe patients was significantly higher than that of mild patients. Therefore, hyaluronic acid inhibitors have the potential to be the treatment of novel coronavirus pneumonia. This study plans to carry out a study on the optimization of the hyaluronic acid inhibitor Hymecromone in the treatment of COVID-19 to improve the therapeutic effect.Methods and analysisThis is a single-center, randomized, parallel controlled, double-blind clinical trial designed to evaluate the efficacy and safety of hymecromone tablets in subjects who confirmed to be infected by the SARS-CoV-2 virus and diagnosed as mild or moderate novel coronavirus pneumonia in China. The subjects in the experimental arm shall receive necessary routine treatment and hymecromone tablets while the control arm shall receive placebo. The study aims to compare the proportion of subjects in the experimental group and the control group who developed disease progression within 28 days after initial treatment. Meanwhile, all subjects will be monitored for safety constantly during the whole study phases.Ethics and disseminationThe study protocol was approved by the Ethics Committee of Zhongshan Hospital Fudan University (identifiers: Clinical Ethical Approval No. B2022-251R).Trial registrationClinicalTrails.org, NCT05386420. Registered 24 May 2022, https://clinicaltrials.gov/ct2/show/NCT05386420Strengths and limitations of this studyThis is one of the first prospective randomized controlled double-blind studies of the efficacy and safety of the hyaluronic acid inhibitor Hymecromone for the treatment of COVID-19. This study will be an innovative clinical intervention strategy, and is expected to provide an effective new treatment plan for the clinical treatment of severe infection with COVID-19. The limitation is it is a single center study, it might need more centers cases to be further external validated.INTRODUCTION
Subject(s)
COVID-19ABSTRACT
Introduction: During the COVID-19 epidemic in Singapore, there was an urgent demand to train more nurses within a short timeframe to perform the Water Swallow Test (WST). The previous training model involved training with actual patients and was time-consuming. Hence, the model was revamped and standardised patients (SPs) were engaged for nurses' training. This study further investigated nurses' feedback about the new training model and compared the efficiency and learner-reported outcomes of the previous and new models. Methods: Nurses who completed WST training from January 2018 to July 2020 were enrolled. Training records were accessed to determine the number of nurses trained under the previous and new models. Nurses were invited to complete post-training evaluation forms and their responses were analysed. Descriptive statistics and the Mann-Whitney U test were used for data analysis. Results: Under the previous model, 52 nurses were trained over 2 years, whereas under the new model, 112 nurses were trained over two months. From the evaluation form responses, the majority of nurses trained under the new model agreed that they achieved the learning objectives and were confident in performing the WST. There was also no significant difference (p>0.05) found between learner-reported outcomes for both training models. Conclusion: Our findings demonstrated that the new model that engaged SPs was more efficient in training more nurses. Nurses were also satisfied with the new training model, which achieved similar learner-reported outcomes as the previous model. [ABSTRACT FROM AUTHOR] Copyright of Asia Pacific Scholar is the property of Centre for Medical Education (CenMed) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
ABSTRACT
In late 2019, the novel coronavirus 2019 (COVID-19) outbreak was first identified in Wuhan, China, and subsequently spread worldwide. By July 11, 2020, the number of confirmed COVID-19 cases reached 12,881,555 (including 599,146 deaths) in 187 countries/ territories. The pandemic has not reach its peak yet. The situations of epidemics in the United States, Central and South Americas, and South Asia were still serious. Some countries faced re-surging epidemic after lifting restrictions. In Taiwan, the first imported case and the indigenous case were reported on January 21, and 28, respectively. As of July 12, the cumulative number of confirmed cases was 451, including 360 imported cases, 55 indigenous cases, and another 36 cases of naval crew members aboard the Panshi fast combat support ship. Currently the COVID-19 cases in Taiwan were still sporadic imported cases. No locally-acquired case was found for more than 8 weeks. Based on the current epidemic status, the risks of imported cases are still high. The high transmissibility of the virus and the potential of community outbreak remained as a threat to Taiwan's health system and society. Therefore, the overall risk of COVID-19 is considered high domestically.